<?xml version="1.0" encoding="UTF-8"?>
<clinical_study rank="234905">
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on April 10, 2017</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT00014859</url>
  </required_header>
  <id_info>
    <org_study_id>967</org_study_id>
    <nct_id>NCT00014859</nct_id>
    <nct_alias>NCT00200915</nct_alias>
  </id_info>
  <brief_title>Epidemiology of Surfactant Protein-B Deficiency</brief_title>
  <official_title>Epidemiology of Surfactant Protein-B Deficiency</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Washington University School of Medicine</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>Washington University School of Medicine</source>
  <oversight_info>
    <has_dmc>No</has_dmc>
  </oversight_info>
  <brief_summary>
    <textblock>
      The purpose of this study is to test the hypothesis that excess, rare, functionally
      disruptive single nucleotide polymorphisms (SNPs) characterize genes (e.g., the surfactant
      protein-B gene)(SFTPB) and gene networks (e.g., the pulmonary surfactant metabolic network)
      associated with increased risk of neonatal respiratory distress syndrome (RDS).
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      BACKGROUND:

      Respiratory distress syndrome is the most frequent respiratory cause of death and morbidity
      in infants less than 1 year of age in the United States. Of approximately 28,500 infant
      deaths in 2006, 5,421 (19.7%) were diagnosed with respiratory distress as either the primary
      (1,011 - 3.7%) or secondary (4,410 - 16%) cause of death. Despite improvement in infant
      mortality rates over the last 20 years, survivors of respiratory distress syndrome with
      chronic respiratory disease consume twenty times more annualized dollars than unaffected
      children and 5.9% of all dollars spent on children from 0-18 years of age. More recent
      estimates including data from California and New York, the Institute of Medicine, and the
      2001 Nationwide Inpatient Sample from the Healthcare Cost and Utilization Project suggest
      that the average cost of hospitalization for each of the 49,900 infants with a diagnosis of
      respiratory distress syndrome was $56,800 vs. $10,700 for a premature infant without
      respiratory distress syndrome. The recent increase in late preterm births has contributed to
      both the frequency of respiratory distress syndrome and its economic impact. These medical
      costs do not include the economic consequences of infant respiratory morbidity for families,
      e.g., absence from work, and early intervention costs to optimize outcome. In addition,
      despite 2-3 fold greater risk of infant mortality for African American infants than European
      American infants from all other causes, European American infants have greater risk of death
      from respiratory distress than African American infants, and this increased risk is not
      attributable to differences in surfactant phospholipid composition, birth weight,
      gestational age, or confounding socioeconomic factors. Understanding the genetic mechanisms
      that cause respiratory distress syndrome is critical for improving outcomes of children in
      the United States, reducing costs of their health care, and reducing racial disparity in
      infant mortality. Since the original description of deficiency of the pulmonary surfactant
      in premature newborn infants by Avery and Mead in 1959, respiratory distress syndrome has
      most commonly been attributed to developmental immaturity of pulmonary surfactant
      production. Despite improvement in neonatal survival associated with availability of
      surfactant replacement therapy for premature infants, gender and race based disparities in
      disease frequency, morbidity and mortality have persisted, an observation that suggests that
      genetic factors play an important role in disease pathogenesis. In addition, twin studies
      indicate high heritability (h2) of neonatal respiratory distress syndrome (0.2 and 0.8).
      Recent clinical reports of monogenic causes of neonatal respiratory distress syndrome,
      statistical association of candidate gene variants with increased disease risk, and studies
      of targeted gene ablation in murine lineages have also strongly suggested that genetic
      mechanisms contribute to risk of respiratory distress syndrome in newborn infants. When we
      examined genetic variants in large population-based and case-control cohorts, we found that
      the population-based frequencies of individual, disruptive mutations in 3 candidate genes
      (SFTPB, SFTPC, and ABCA3) (&lt;2%) account for &lt;0.1% of the population attributable risk in
      term or near term infants, and that individual, rare, disruptive mutations are not
      associated with disease in case-control cohorts. In addition, when we attempted to establish
      an association between an intermediate biochemical phenotype (surfactant protein-B peptide
      mobility on western blot) and SFTPB variants (assessed by complete resequencing) in term and
      near term infants with and without respiratory distress, we failed to identify a SFTPB
      variant or combination of variants associated with respiratory distress and altered
      surfactant protein-B structure. Finally, we have recently found that tagSNPs in genes from
      gene networks expressed in lung but not part of the pulmonary surfactant network (ion
      channel, lung remodeling, and unfolded protein response genes) confer race-specific risk of
      neonatal respiratory distress syndrome. These studies suggest that variation in SFTPB,
      SFTPC, and ABCA3 is under significant purifying selection pressure and that the genetic
      contribution to neonatal respiratory distress syndrome is based on contributions of rare,
      independent risk alleles in multiple genes and gene networks.

      DESIGN NARRATIVE:

      Rare mutations in the surfactant protein-B gene (SFTPB) and other genes in the pulmonary
      surfactant metabolic network cause lethal neonatal respiratory distress syndrome in human
      newborn infants by disrupting metabolism and function of the pulmonary surfactant. Mutation
      frequencies (&lt;1-2%) in SFTPB and 2 other candidate genes in the pulmonary surfactant network
      (SFTPC and ABCA3) do not account for heritability of neonatal respiratory distress syndrome
      (h2~0.2-0.8) suggested by twin studies. To develop a comprehensive catalogue of genes and
      gene networks that account for the heritability of this complex disease, we propose to test
      the hypothesis that excess, rare, functionally disruptive single nucleotide polymorphisms
      (SNPs) characterize genes and gene networks associated with increased risk of neonatal
      respiratory distress syndrome. Specifically, using an agnostic candidate gene identification
      algorithm and the Kyoto Encyclopedia of Genes and Genomes (KEGG) Pathway Database, we will
      select a comprehensive list of genes (~2,000) and their cognate gene networks expressed in
      human lung. Next, to identify a subgroup of genes (N=250) and gene networks with excess,
      rare, disruptive exonic SNPs associated with neonatal respiratory distress syndrome, we will
      use hybridization selection/exon capture, next-generation sequencing technology, and new
      statistical strategies (e.g., Combined Multivariate and Collapsing (CMC) method) in a
      case-control cohort (N=250 cases, 250 controls) sized to provide adequate statistical power
      (&gt;0.8). Finally, to validate the highest risk genes and to optimize statistical power to
      search for epistatic and network x network interactions that confer disease risk, we will
      use CMC, Bayesian, and logic tree methods to analyze exonic SNPs in a second case-control
      cohort (N=100 cases, 100 controls) also sized to provide adequate statistical power (&gt;0.8).
      Using next-generation sequencing technology and state of the art statistical methods to
      elucidate the genetic complexity of neonatal respiratory distress syndrome will permit the
      development of personalized diagnostic tools and preventive therapeutic strategies that
      target whole gene networks rather than individual genes.
    </textblock>
  </detailed_description>
  <overall_status>Recruiting</overall_status>
  <start_date>June 2001</start_date>
  <completion_date type="Anticipated">June 2019</completion_date>
  <primary_completion_date type="Actual">June 2015</primary_completion_date>
  <phase>N/A</phase>
  <study_type>Observational [Patient Registry]</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <observational_model>Case Control</observational_model>
    <time_perspective>Prospective</time_perspective>
  </study_design_info>
  <target_duration>4 Weeks</target_duration>
  <primary_outcome>
    <measure>Statistical association of rare, functionally disruptive genomic variant with RDS</measure>
    <time_frame>4 weeks</time_frame>
    <description>Using custom exon capture, next generation sequencing, and in silico prediction of function, discover statistical associations between gene loci with excess, rare, functionally disruptive variants and risk of neonatal respiratory distress syndrome.</description>
  </primary_outcome>
  <secondary_outcome>
    <measure>Statistical associations between risk of neonatal respiratory distress syndrome and excess, rare functional variants in gene pathways</measure>
    <time_frame>4 weeks</time_frame>
    <description>Using custom exon capture, next generation sequencing, in silico prediction of functional variants, and Metacore for pathway construction, identify statistical associations between risk of neonatal respiratory distress syndrome and pathways with excess, rare functional variants</description>
  </secondary_outcome>
  <number_of_groups>2</number_of_groups>
  <enrollment type="Anticipated">5000</enrollment>
  <condition>Lung Diseases</condition>
  <condition>Respiratory Distress Syndrome, Newborn</condition>
  <condition>Pulmonary Surfactants</condition>
  <arm_group>
    <arm_group_label>I</arm_group_label>
    <description>Descriptive cohort of population-based DNA samples from the newborn screening program in Missouri with vital statistics based, linked phenotype data</description>
  </arm_group>
  <arm_group>
    <arm_group_label>II</arm_group_label>
    <description>Case-control cohort of infants with and without neonatal respiratory distress syndrome</description>
  </arm_group>
  <biospec_retention>Samples With DNA</biospec_retention>
  <biospec_descr>
    <textblock>
      DNA and tracheal aspirate samples
    </textblock>
  </biospec_descr>
  <eligibility>
    <study_pop>
      <textblock>
        Cohort I is a population-based cohort from Missouri. Cohort II is a case-control cohort
        from the Neonatal Intensive Care Unit at St. Louis Children's Hospital and from patients
        referred from other centers.
      </textblock>
    </study_pop>
    <sampling_method>Non-Probability Sample</sampling_method>
    <criteria>
      <textblock>
        Inclusion Criteria:

          -  Normal pulmonary function or a diagnosis of RDS

        Exclusion Criteria:
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>N/A</minimum_age>
    <maximum_age>1 Year</maximum_age>
    <healthy_volunteers>Accepts Healthy Volunteers</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>F. Sessions Cole, MD</last_name>
    <role>Principal Investigator</role>
    <affiliation>Washington University School of Medicine</affiliation>
  </overall_official>
  <location>
    <facility>
      <name>Washington University School of Medicine</name>
      <address>
        <city>St. Louis</city>
        <state>Missouri</state>
        <zip>63110</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>F. Sessions Cole, MD</last_name>
      <phone>314-454-6148</phone>
      <email>cole@kids.wustl.edu</email>
    </contact>
  </location>
  <location_countries>
    <country>United States</country>
  </location_countries>
  <reference>
    <citation>Nogee LM. Abnormal expression of surfactant protein C and lung disease. Am J Respir Cell Mol Biol. 2002 Jun;26(6):641-4.</citation>
    <PMID>12034561</PMID>
  </reference>
  <reference>
    <citation>Merchak A, Janssen DJ, Bohlin K, Patterson BW, Zimmermann LJ, Carnielli VP, Hamvas A. Endogenous pulmonary surfactant metabolism is not affected by mode of ventilation in premature infants with respiratory distress syndrome. J Pediatr. 2002 Jun;140(6):693-8.</citation>
    <PMID>12072872</PMID>
  </reference>
  <reference>
    <citation>Cole FS. Surfactant protein B: unambiguously necessary for adult pulmonary function. Am J Physiol Lung Cell Mol Physiol. 2003 Sep;285(3):L540-2. Review.</citation>
    <PMID>12902317</PMID>
  </reference>
  <reference>
    <citation>Nogee LM. Genetic mechanisms of surfactant deficiency. Biol Neonate. 2004;85(4):314-8. Epub 2004 Jun 8. Review.</citation>
    <PMID>15218289</PMID>
  </reference>
  <reference>
    <citation>Hamvas A, Nogee LM, White FV, Schuler P, Hackett BP, Huddleston CB, Mendeloff EN, Hsu FF, Wert SE, Gonzales LW, Beers MF, Ballard PL. Progressive lung disease and surfactant dysfunction with a deletion in surfactant protein C gene. Am J Respir Cell Mol Biol. 2004 Jun;30(6):771-6. Epub 2003 Dec 4.</citation>
    <PMID>14656744</PMID>
  </reference>
  <reference>
    <citation>Cameron HS, Somaschini M, Carrera P, Hamvas A, Whitsett JA, Wert SE, Deutsch G, Nogee LM. A common mutation in the surfactant protein C gene associated with lung disease. J Pediatr. 2005 Mar;146(3):370-5.</citation>
    <PMID>15756222</PMID>
  </reference>
  <reference>
    <citation>Palomar LM, Nogee LM, Sweet SC, Huddleston CB, Cole FS, Hamvas A. Long-term outcomes after infant lung transplantation for surfactant protein B deficiency related to other causes of respiratory failure. J Pediatr. 2006 Oct;149(4):548-53.</citation>
    <PMID>17011330</PMID>
  </reference>
  <reference>
    <citation>Cole FS, Nogee LM, Hamvas A. Defects in surfactant synthesis: clinical implications. Pediatr Clin North Am. 2006 Oct;53(5):911-27, ix. Review.</citation>
    <PMID>17027617</PMID>
  </reference>
  <reference>
    <citation>Tomazela DM, Patterson BW, Hanson E, Spence KL, Kanion TB, Salinger DH, Vicini P, Barret H, Heins HB, Cole FS, Hamvas A, MacCoss MJ. Measurement of human surfactant protein-B turnover in vivo from tracheal aspirates using targeted proteomics. Anal Chem. 2010 Mar 15;82(6):2561-7. doi: 10.1021/ac1001433.</citation>
    <PMID>20178338</PMID>
  </reference>
  <reference>
    <citation>Wambach JA, Yang P, Wegner DJ, An P, Hackett BP, Cole FS, Hamvas A. Surfactant protein-C promoter variants associated with neonatal respiratory distress syndrome reduce transcription. Pediatr Res. 2010 Sep;68(3):216-20. doi: 10.1203/00006450-201011001-00421.</citation>
    <PMID>20539253</PMID>
  </reference>
  <results_reference>
    <citation>Hamvas A, Madden KK, Nogee LM, Trusgnich MA, Wegner DJ, Heins HB, Cole FS. Informed consent for genetic research. Arch Pediatr Adolesc Med. 2004 Jun;158(6):551-5.</citation>
    <PMID>15184218</PMID>
  </results_reference>
  <results_reference>
    <citation>Hamvas A, Wegner DJ, Trusgnich MA, Madden K, Heins H, Liu Y, Rice T, An P, Watkins-Torry J, Cole FS. Genetic variant characterization in intron 4 of the surfactant protein B gene. Hum Mutat. 2005 Nov;26(5):494-5.</citation>
    <PMID>16211553</PMID>
  </results_reference>
  <results_reference>
    <citation>Wilson RK, Ley TJ, Cole FS, Milbrandt JD, Clifton S, Fulton L, Fewell G, Minx P, Sun H, McLellan M, Pohl C, Mardis ER. Mutational profiling in the human genome. Cold Spring Harb Symp Quant Biol. 2003;68:23-9. Review.</citation>
    <PMID>15338599</PMID>
  </results_reference>
  <results_reference>
    <citation>Wegner DJ, Hertzberg T, Heins HB, Elmberger G, MacCoss MJ, Carlson CS, Nogee LM, Cole FS, Hamvas A. A major deletion in the surfactant protein-B gene causing lethal respiratory distress. Acta Paediatr. 2007 Apr;96(4):516-20.</citation>
    <PMID>17391469</PMID>
  </results_reference>
  <results_reference>
    <citation>Hamvas A, Wegner DJ, Carlson CS, Bergmann KR, Trusgnich MA, Fulton L, Kasai Y, An P, Mardis ER, Wilson RK, Cole FS. Comprehensive genetic variant discovery in the surfactant protein B gene. Pediatr Res. 2007 Aug;62(2):170-5.</citation>
    <PMID>17597650</PMID>
  </results_reference>
  <results_reference>
    <citation>Saugstad OD, Hansen TW, Rønnestad A, Nakstad B, Tølløfsrud PA, Reinholt F, Hamvas A, Coles FS, Dean M, Wert SE, Whitsett JA, Nogee LM. Novel mutations in the gene encoding ATP binding cassette protein member A3 (ABCA3) resulting in fatal neonatal lung disease. Acta Paediatr. 2007 Feb;96(2):185-90.</citation>
    <PMID>17429902</PMID>
  </results_reference>
  <results_reference>
    <citation>Garmany TH, Wambach JA, Heins HB, Watkins-Torry JM, Wegner DJ, Bennet K, An P, Land G, Saugstad OD, Henderson H, Nogee LM, Cole FS, Hamvas A. Population and disease-based prevalence of the common mutations associated with surfactant deficiency. Pediatr Res. 2008 Jun;63(6):645-9. doi: 10.1203/PDR.0b013e31816fdbeb.</citation>
    <PMID>18317237</PMID>
  </results_reference>
  <results_reference>
    <citation>McBee AD, Wegner DJ, Carlson CS, Wambach JA, Yang P, Heins HB, Saugstad OD, Trusgnich MA, Watkins-Torry J, Nogee LM, Henderson H, Cole FS, Hamvas A. Recombination as a mechanism for sporadic mutation in the surfactant protein-C gene. Pediatr Pulmonol. 2008 May;43(5):443-50. doi: 10.1002/ppul.20782.</citation>
    <PMID>18383112</PMID>
  </results_reference>
  <results_reference>
    <citation>Hamvas A, Heins HB, Guttentag SH, Wegner DJ, Trusgnich MA, Bennet KW, Yang P, Carlson CS, An P, Cole FS. Developmental and genetic regulation of human surfactant protein B in vivo. Neonatology. 2009;95(2):117-24. doi: 10.1159/000153095. Epub 2008 Sep 6.</citation>
    <PMID>18776725</PMID>
  </results_reference>
  <results_reference>
    <citation>Druley TE, Vallania FL, Wegner DJ, Varley KE, Knowles OL, Bonds JA, Robison SW, Doniger SW, Hamvas A, Cole FS, Fay JC, Mitra RD. Quantification of rare allelic variants from pooled genomic DNA. Nat Methods. 2009 Apr;6(4):263-5. doi: 10.1038/nmeth.1307. Epub 2009 Mar 1.</citation>
    <PMID>19252504</PMID>
  </results_reference>
  <results_reference>
    <citation>Hamvas A, Nogee LM, Wegner DJ, Depass K, Christodoulou J, Bennetts B, McQuade LR, Gray PH, Deterding RR, Carroll TR, Kammesheidt A, Kasch LM, Kulkarni S, Cole FS. Inherited surfactant deficiency caused by uniparental disomy of rare mutations in the surfactant protein-B and ATP binding cassette, subfamily a, member 3 genes. J Pediatr. 2009 Dec;155(6):854-859.e1. doi: 10.1016/j.jpeds.2009.06.006. Epub 2009 Aug 3.</citation>
    <PMID>19647838</PMID>
  </results_reference>
  <results_reference>
    <citation>Anadkat JS, Kuzniewicz MW, Chaudhari BP, Cole FS, Hamvas A. Increased risk for respiratory distress among white, male, late preterm and term infants. J Perinatol. 2012 Oct;32(10):780-5. doi: 10.1038/jp.2011.191. Epub 2012 Jan 5.</citation>
    <PMID>22222548</PMID>
  </results_reference>
  <results_reference>
    <citation>Agrawal A, Hamvas A, Cole FS, Wambach JA, Wegner D, Coghill C, Harrison K, Nogee LM. An intronic ABCA3 mutation that is responsible for respiratory disease. Pediatr Res. 2012 Jun;71(6):633-7. doi: 10.1038/pr.2012.21. Epub 2012 Feb 15.</citation>
    <PMID>22337229</PMID>
  </results_reference>
  <results_reference>
    <citation>Bereman MS, Tomazela DM, Heins HS, Simonato M, Cogo PE, Hamvas A, Patterson BW, Cole FS, MacCoss MJ. A method to determine the kinetics of multiple proteins in human infants with respiratory distress syndrome. Anal Bioanal Chem. 2012 Jun;403(8):2397-402. doi: 10.1007/s00216-012-5953-3. Epub 2012 Apr 14.</citation>
    <PMID>22526637</PMID>
  </results_reference>
  <results_reference>
    <citation>Wambach JA, Wegner DJ, Depass K, Heins H, Druley TE, Mitra RD, An P, Zhang Q, Nogee LM, Cole FS, Hamvas A. Single ABCA3 mutations increase risk for neonatal respiratory distress syndrome. Pediatrics. 2012 Dec;130(6):e1575-82. doi: 10.1542/peds.2012-0918. Epub 2012 Nov 19.</citation>
    <PMID>23166334</PMID>
  </results_reference>
  <results_reference>
    <citation>Hamvas A, Deterding RR, Wert SE, White FV, Dishop MK, Alfano DN, Halbower AC, Planer B, Stephan MJ, Uchida DA, Williames LD, Rosenfeld JA, Lebel RR, Young LR, Cole FS, Nogee LM. Heterogeneous pulmonary phenotypes associated with mutations in the thyroid transcription factor gene NKX2-1. Chest. 2013 Sep;144(3):794-804. doi: 10.1378/chest.12-2502.</citation>
    <PMID>23430038</PMID>
  </results_reference>
  <results_reference>
    <citation>Sen P, Yang Y, Navarro C, Silva I, Szafranski P, Kolodziejska KE, Dharmadhikari AV, Mostafa H, Kozakewich H, Kearney D, Cahill JB, Whitt M, Bilic M, Margraf L, Charles A, Goldblatt J, Gibson K, Lantz PE, Garvin AJ, Petty J, Kiblawi Z, Zuppan C, McConkie-Rosell A, McDonald MT, Peterson-Carmichael SL, Gaede JT, Shivanna B, Schady D, Friedlich PS, Hays SR, Palafoll IV, Siebers-Renelt U, Bohring A, Finn LS, Siebert JR, Galambos C, Nguyen L, Riley M, Chassaing N, Vigouroux A, Rocha G, Fernandes S, Brumbaugh J, Roberts K, Ho-Ming L, Lo IF, Lam S, Gerychova R, Jezova M, Valaskova I, Fellmann F, Afshar K, Giannoni E, Muhlethaler V, Liang J, Beckmann JS, Lioy J, Deshmukh H, Srinivasan L, Swarr DT, Sloman M, Shaw-Smith C, van Loon RL, Hagman C, Sznajer Y, Barrea C, Galant C, Detaille T, Wambach JA, Cole FS, Hamvas A, Prince LS, Diderich KE, Brooks AS, Verdijk RM, Ravindranathan H, Sugo E, Mowat D, Baker ML, Langston C, Welty S, Stankiewicz P. Novel FOXF1 mutations in sporadic and familial cases of alveolar capillary dysplasia with misaligned pulmonary veins imply a role for its DNA binding domain. Hum Mutat. 2013 Jun;34(6):801-11. doi: 10.1002/humu.22313. Epub 2013 Apr 12.</citation>
    <PMID>23505205</PMID>
  </results_reference>
  <results_reference>
    <citation>Wambach JA, Casey AM, Fishman MP, Wegner DJ, Wert SE, Cole FS, Hamvas A, Nogee LM. Genotype-phenotype correlations for infants and children with ABCA3 deficiency. Am J Respir Crit Care Med. 2014 Jun 15;189(12):1538-43. doi: 10.1164/rccm.201402-0342OC.</citation>
    <PMID>24871971</PMID>
  </results_reference>
  <results_reference>
    <citation>Wambach JA, Wegner DJ, Heins HB, Druley TE, Mitra RD, Hamvas A, Cole FS. Synonymous ABCA3 variants do not increase risk for neonatal respiratory distress syndrome. J Pediatr. 2014 Jun;164(6):1316-21.e3. doi: 10.1016/j.jpeds.2014.02.021. Epub 2014 Mar 20.</citation>
    <PMID>24657120</PMID>
  </results_reference>
  <verification_date>June 2015</verification_date>
  <lastchanged_date>June 1, 2015</lastchanged_date>
  <firstreceived_date>April 11, 2001</firstreceived_date>
  <responsible_party>
    <responsible_party_type>Principal Investigator</responsible_party_type>
    <investigator_affiliation>Washington University School of Medicine</investigator_affiliation>
    <investigator_full_name>F. Sessions Cole, MD</investigator_full_name>
    <investigator_title>Professor of Pediatrics</investigator_title>
  </responsible_party>
  <keyword>Pulmonary surfactant</keyword>
  <keyword>Surfactant protein B</keyword>
  <keyword>Surfactant protein C</keyword>
  <keyword>ABCA3</keyword>
  <keyword>NKX2-1</keyword>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm  -->
    <mesh_term>Lung Diseases</mesh_term>
    <mesh_term>Respiratory Distress Syndrome, Newborn</mesh_term>
    <mesh_term>Respiratory Distress Syndrome, Adult</mesh_term>
    <mesh_term>Pulmonary Alveolar Proteinosis</mesh_term>
  </condition_browse>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm  -->
    <mesh_term>Pulmonary Surfactants</mesh_term>
  </intervention_browse>
  <!-- Results have not yet been posted for this study                                -->
</clinical_study>
